Evaluation of the Possible Interaction of the Antifungal Triazole SCH 39304 with Oral Contraceptives in Normal Healthy Women

Lunell, Nils‐Olov; Pschera, Helmut; Zador, Göran; Carlström, Kjell

doi:10.1159/000293003

Cited by 7 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most broad-spectrum antibiotics do not affect the contraceptive effectiveness of COCs, patch (345), or ring(346). Studies of antifungal agents have shown no clinically significant pharmacokinetic interactions with COCs(347)(348)(349)(350)(351)(352)(353)(354)(355)(356), or ring(357). Studies of antiparasitic agents have shown no clinically significant pharmacokinetic interactions with COCs(236,(358)(359)(360)(361)(362).…”

mentioning

confidence: 99%

U.S. Medical Eligibility Criteria for Contraceptive Use, 2016

et al. 2016

View full text Add to dashboard Cite

The 2016 U.S. Medical Eligibility Criteria for Contraceptive Use (U.S. MEC) comprises recommendations for the use of specific contraceptive methods by women and men who have certain characteristics or medical conditions. These recommendations for health care providers were updated by CDC after review of the scientific evidence and consultation with national experts who met in Atlanta, Georgia, during August 26-28, 2015. The information in this report updates the 2010 U.S. MEC (CDC. U.S. medical eligibility criteria for contraceptive use, 2010. MMWR 2010:59 [No. RR-4]). Notable updates include the addition of recommendations for women with cystic fibrosis, women with multiple sclerosis, and women receiving certain psychotropic drugs or St. John's wort; revisions to the recommendations for emergency contraception, including the addition of ulipristal acetate; and revisions to the recommendations for postpartum women; women who are breastfeeding; women with known dyslipidemias, migraine headaches, superficial venous disease, gestational trophoblastic disease, sexually transmitted diseases, and human immunodeficiency virus; and women who are receiving antiretroviral therapy. The recommendations in this report are intended to assist health care providers when they counsel women, men, and couples about contraceptive method choice. Although these recommendations are meant to serve as a source of clinical guidance, health care providers should always consider the individual clinical circumstances of each person seeking family planning services. This report is not intended to be a substitute for professional medical advice for individual patients. Persons should seek advice from their health care providers when considering family planning options.

show abstract

mentioning

confidence: 99%

U.S. Medical Eligibility Criteria for Contraceptive Use, 2016

et al. 2016

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

CE: An Evidence-Based Update on Contraception

Britton

Alspaugh

Greene

et al. 2020

AJN, American Journal of Nursing

View full text Add to dashboard Cite

Recommendations and Reports Disclosure of Relationship CDC, our planners, and our content experts wish to disclose they have no financial interest or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters. Planners have reviewed content to ensure there is no bias. This document will not include any discussion of the unlabeled use of a product or a product under investigational use, with the exception that some of the recommendations in this document might be inconsistent with package labeling.

show abstract